Prognia
Drug Database
🇪🇺EU · EMAAuthorisedATC: B02BD02

Advate(octocog alfa)

Hemophilia A

Marketing Authorisation Holder: Takeda Manufacturing Austria AG

EMA Authorisation: 02/03/2004

INN: octocog alfa

Indication

Treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor-VIII deficiency). Advate does not contain von Willebrand factor in pharmacologically effective quantities and is therefore not indicated in von Willebrand disease.

Official EMA Resources

View on EMA (ema.europa.eu)

AI Drug & Interaction Analysis

Free account required

Ask Prognia AI about Advate — dosing recommendations, drug interactions, and current guideline evidence from ESC, EMA, NICE and more.

Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.